Antiplatelet Therapy for AIS Patients With Thrombocytopenia

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.

Detailed Description
-----------------
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.

Official Title
-----------------
Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia

Conditions
-----------------
Acute Ischemic Stroke, Thrombocytopenia

Intervention / Treatment
-----------------
* Drug: aspirin, clopidogrel, cilostazol, and dipyridamole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years old Acute ischemic stroke or transient ischemic attack with onset < 7 days The last blood routine test before enrollment indicates platelet count < 100 x 10^9 and > 30 x 10^9 Exclusion Criteria: Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury Indications for anticoagulation therapy, e.g. atrial fibrillation Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past Have or plan to receive CEA or CAS in the following 3 months Life expectancy less than 1 year Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding Pregnant or lactating women Individuals identified by researchers as unsuitable for participation in the study due to other reasons.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole. | Drug: aspirin, clopidogrel, cilostazol, and dipyridamole<br>* Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.<br>* Other names: Antiplatelet Agents;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 90-day Composite events | Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 90-day ischemic stroke | Ischemic stroke within 90 days after enrollment | 90 days | 
| 90-day hemorrhagic stroke | Hemorrhagic stroke within 90 days after enrollment | 90 days | 
| 90-day myocardial infarction | Myocardial infarction within 90 days after enrollment | 90 days | 
| 90-day major extracranial hemorrhage | Major extracranial hemorrhage within 90 days after enrollment | 90 days | 
| 90-day non-major bleeding | Non-major bleeding within 90 days after enrollment | 90 days | 
| 90-day vascular death | Vascular death within 90 days after enrollment | 90 days | 
| 90-day all-cause death | All-cause death within 90 days after enrollment | 90 days | 
| Discharge mRS | Modified Rankin scale at discharge | Through hospitalization, an average of 7 days |